A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.
MUSK, a vision-language model, enhances cancer diagnosis by integrating multimodal data, outperforming existing methods in prognosis and treatment predictions.